Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMHM | ISIN: US00289Y2063 | Ticker-Symbol: PCJ
Tradegate
06.06.25 | 16:58
5,800 Euro
+2,65 % +0,150
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ABEONA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ABEONA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,8005,85017:26
5,8005,85017:26

Aktuelle News zur ABEONA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAbeona Therapeutics auf Jefferies-Konferenz: Vielversprechender Start von ZivaSkin3
MoOppenheimer assumes coverage on Abeona Therapeutics stock8
MoAbeona Therapeutics Inc.: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)50CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
► Artikel lesen
ABEONA THERAPEUTICS Aktie jetzt für 0€ handeln
22.05.DelveInsight Business Research, LLP: ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight301Approximately a year after the FDA rejected its previous approval submission, Abeona announced that the agency had approved ZEVASKYN, its autologous cell-based gene therapy for both adult...
► Artikel lesen
19.05.ABEONA THERAPEUTICS INC. - 8-K, Current Report3
16.05.Abeona targets treating 10-14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway6
15.05.Abeona Therapeutics GAAP EPS of -$0.24 beats by $0.124
15.05.Abeona Therapeutics Inc.: Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates116- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand...
► Artikel lesen
15.05.ABEONA THERAPEUTICS INC. - 10-Q, Quarterly Report1
14.05.Abeona Therapeutics Inc.: Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder2
14.05.Abeona Therapeutics Inc.: Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder2
13.05.Abeona secures cash runway with $155m priority review voucher sale4
12.05.Abeona sells speedy drug review voucher for $155M2
12.05.Abeona nets $155M with FDA voucher sale just 2 weeks after gene therapy approval5
12.05.Abeona sells FDA voucher for $155 million, eyes profitability3
12.05.Abeona verkauft FDA-Gutschein für 155 Millionen US-Dollar und strebt Rentabilität an9
12.05.Abeona Therapeutics Inc.: Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million166CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority...
► Artikel lesen
12.05.ABEONA THERAPEUTICS INC. - 8-K, Current Report1
07.05.Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)86CLEVELAND, May 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards...
► Artikel lesen
01.05.FDA approves Abeona's epidermolysis bullosa gene therapy Zevaskyn3
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1